patient death

Gene editing CRISPR gene therapy
Biotech

After 2 undisclosed deaths, can China’s IIT still be trusted?

Seeing the deaths as proof that the investigator-initiated trials (IIT) pathway is unreliable ignores new guardrails added by China, experts told Fierce.
Angus Liu , Darren Incorvaia Aug 17, 2026 7:20am
Emergency room sign

FDA issues alert in wake of BD recall of faulty needle sets

Aug 10, 2026 8:12am
dominoes stop stall halt end red

FDA hits Newron schizophrenia ph. 3 trial with hold after death

Apr 29, 2026 2:50pm
pause halt pause button

FDA freezes enrollment in MacroGenics cancer trial after death

Feb 24, 2026 2:00pm
gold arrow pointing upward forward

FDA frees Intellia of 1 clinical hold for CRISPR therapy

Jan 27, 2026 10:54am
Curtains closing on an empty stage

Pulmocide pulls ph. 3 antifungal trial over mortality rate

Jan 7, 2026 10:57am